Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05804318 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer

Study acronym: ARTIA-Prostate
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jul 2026 → Jan 2027
See other at-risk trials from Varian, a Siemens Healthineers Company

Record History

  1. Primary completion pushed from Jul 2026 to Jan 2027
    • Study completion pushed from Jul 2031 to Oct 2031
    v10
  2. Study sites: 7 to 8v9
  3. Site details revised at 1 of 7 sitesv8
  4. Study sites: 5 to 7v7
  5. Primary completion date: Mar 2025 to Jul 2026
    • Study sites: 4 to 5
    • Study completion date: Mar 2030 to Jul 2031
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 2 to 4v5
  2. Site details revised at 1 of 2 sitesv4
  3. Study sites: 1 to 2v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2023 to Apr 13, 2023
    • Site details revised
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is a prospective, single-arm, multi-center clinical trial designed to assess whether adaptive radiotherapy with urethral sparing for low to intermediate risk localized prostate cancer will translate into a decreased rate of patient reported acute urinary side effects, as measured by the patient reported EPIC-26 questionnaire, compared with the historically reported rate for non-adaptive, non-urethral sparing prostate SBRT.
Trial Details
NCT Number NCT05804318
Lead Sponsor Varian, a Siemens Healthineers Company
Conditions
(from sponsor)		 Prostate Cancer
Related terms Prostatic Neoplasms
Enrollment 132 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov